A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

NCT07572006 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Neoplasms

Interventions

DRUG: JNJ-95804306
DRUG: AML SoC
DRUG: CLL/SLL SoC

Sponsor

Janssen Research & Development, LLC